Candel Therapeutics, Inc. CADL Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers SquibbBMY

1.9×-0.9×

AmgenAMGN

4.9×-2.7×

Gilead SciencesGILD

2.2×+1.0×

Replimune GroupREPL

0.4×+0.2×

CG OncologyCGON

0×0.0×

RegenxbioRGNX

1×+0.6×

FAQ

What is Candel Therapeutics, Inc.'s debt-to-equity?

Candel Therapeutics, Inc. (CADL) reported debt-to-equity of 0× in Q1 2026.

How has Candel Therapeutics, Inc.'s debt-to-equity changed year-over-year?

Candel Therapeutics, Inc.'s debt-to-equity decreased by 85.9% year-over-year, from 0.1× to 0×.

What is the long-term trend for Candel Therapeutics, Inc.'s debt-to-equity?

Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s debt-to-equity has grown at a 59.4% compound annual growth rate (CAGR), from 0× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.